About us Contacts Drug interactions: 390 212
Drug search by name

Juxtapid Capsules and Zykadia

Determining the interaction of Juxtapid Capsules and Zykadia and the possibility of their joint administration.

Check result:
Juxtapid Capsules <> Zykadia
Relevance: 24.09.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.CONTRAINDICATED: Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme. When lomitapide (60 mg once daily) was coadministered with the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 9 days), lomitapide peak plasma concentration (Cmax) increased by 15-fold and systemic exposure (AUC) increased by 27-fold compared to administration alone. Concomitant use with moderate CYP450 3A4 inhibitors has not been studied; however, significantly increased lomitapide exposure is similarly expected. MANAGEMENT: Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated. References "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.

Professional:

CONTRAINDICATED: Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme. When lomitapide (60 mg once daily) was coadministered with the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 9 days), lomitapide peak plasma concentration (Cmax) increased by 15-fold and systemic exposure (AUC) increased by 27-fold compared to administration alone. Concomitant use with moderate CYP450 3A4 inhibitors has not been studied; however, significantly increased lomitapide exposure is similarly expected.

MANAGEMENT: Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated.

References
  • "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.
Juxtapid Capsules

Generic Name: lomitapide

Brand name: Juxtapid

Synonyms: Lomitapide

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction